RCUS
Arcus Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +17.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 9.16K | $218,307 | n/a | n/a |
| Q2 2026 | 84 | +2 | 62.09M | $1.91B | +9 | −7 |
| Q1 2026 | 85 | -2 | 57.45M | $1.24B | +6 | −8 |
| Q4 2025 | 87 | -1 | 64.26M | $1.53B | +1 | −2 |
| Q3 2025 | 20 | +2 | 36.84M | $500.99M | +2 | n/a |
| Q2 2025 | 15 | -1 | 35.18M | $286.34M | n/a | −1 |
| Q1 2025 | 13 | +2 | 11.54M | $90.60M | +4 | −2 |
| Q4 2024 | 11 | 0 | 8.18M | $121.86M | +1 | −1 |
| Q3 2024 | 10 | 0 | 4.70M | $71.80M | n/a | n/a |
| Q2 2024 | 10 | n/a | 4.00M | $60.94M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 2.44M | +32.9% | $37.26M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.22M | -0.9% | $18.69M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 317.87K | -32.0% | $4.86M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Millennium Management ✦ | 245.10K | +39.5% | $3.75M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 183.90K | +123.2% | $2.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 135.66K | +29.0% | $2.07M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 77.12K | +544.1% | $1.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 37.21K | +2.0% | $569,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 26.09K | +6.4% | $398,916 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 13.50K | -56.1% | $206,430 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 209 holders, 119.00M shares, $2.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.83K sh · $84,810
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
24.7% of class · View original SEC filing ↗